Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
  • Page of 1
Oshima Y, Tanimoto T, Yuji K. Vibrio vulnificus Infections From a Previously Nonendemic Area. Ann Intern Med. 2020 Mar 3;172(5):367. doi: 10.7326/L19-0757. PubMed PMID: 32120392.
Oshima Y, Tanimoto T, Yuji K, Tojo A. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler. 2019 Jul;25(8):1141-1149. doi: 10.1177/1352458518786075. Epub 2018 Jul 9. PubMed PMID: 29985084.
Oshima Y, Takahashi S, Tani K, Tojo A. Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database. Cytokine. 2019 Jul;119:47-51. doi: 10.1016/j.cyto.2019.02.013. Epub 2019 Mar 13. PubMed PMID: 30875590.
Oshima Y, Tanimoto T, Yuji K, Tojo A. EGFR-TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. JAMA Oncol. 2018 Aug 1;4(8):1112-1115. doi: 10.1001/jamaoncol.2017.4526. PubMed PMID: 29327061; PubMed Central PMCID: PMC5885195.
Oshima Y, Hagino N, Hara M, Ohfuji T. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. Ann Intern Med. 2018 Jul 17;169(2):133. doi: 10.7326/L18-0208. PubMed PMID: 30014108.
Oshima Y, Morishima Y, Ono K, Hirano M, Suzuki K. Comparative Effectiveness of Routine Invasive Coronary Angiography for Managing Unstable Angina. Ann Intern Med. 2017 Dec 5;167(11):836. doi: 10.7326/L17-0521. PubMed PMID: 29204617.
Oshima Y, Tanimoto T, Yuji K, Tojo A. Association between GvHD and nivolumab in the FDA adverse event reporting system. Bone Marrow Transplant. 2017 Oct;52(10):1463-1464. doi: 10.1038/bmt.2017.158. Epub 2017 Jul 31. PubMed PMID: 28759026.
Tanimoto T, Mori J, Oshima Y. Characteristics of Novel Therapeutics and Postmarket Safety Events. JAMA. 2017 Sep 19;318(11):1067. doi: 10.1001/jama.2017.11513. PubMed PMID: 28975300.
Tanimoto T, Oshima Y, Yuji K, Ozaki A, Kami M. Organophosphate Poisoning and Terrorism. Malays J Med Sci. 2017 Aug;24(4):111-112. doi: 10.21315/mjms2017.24.4.14. Epub 2017 Aug 18. PubMed PMID: 28951697; PubMed Central PMCID: PMC5609697.
Oshima Y, Tanimoto T, Yuji K, Tojo A. Association Between Aortic Dissection and Systemic Exposure of Vascular Endothelial Growth Factor Pathway Inhibitors in the Japanese Adverse Drug Event Report Database. Circulation. 2017 Feb 21;135(8):815-817. doi: 10.1161/CIRCULATIONAHA.116.025144. PubMed PMID: 28223329.
Oshima Y, Yuji K, Tojo A. "Imatinib-induced gastric antral vascular ectasia" in a reporting system of the Japanese Adverse Drug Event Report database. Int J Hematol. 2016 May;103(5):596-8. doi: 10.1007/s12185-016-1980-8. Epub 2016 Mar 15. PubMed PMID: 26980219.
Yuji K, Tanimoto T, Oshima Y. 23andMe and the FDA. N Engl J Med. 2014 Jun 5;370(23):2248. doi: 10.1056/NEJMc1404692. PubMed PMID: 24897101.
Tanimoto T, Oshima Y, Kami M. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013 Oct 3;369(14):1378-9. doi: 10.1056/NEJMc1308826. PubMed PMID: 24088109.
Oshima Y, Tsukamoto H, Tojo A. Association of hepatitis B with antirheumatic drugs: a case-control study. Mod Rheumatol. 2013 Jul;23(4):694-704. doi: 10.1007/s10165-012-0709-7. Epub 2012 Jul 18. PubMed PMID: 22802011.
Oshima Y, Yuji K, Tanimoto T, Hinomura Y, Tojo A. Association between acute myelogenous leukemia and thrombopoietin receptor agonists in patients with immune thrombocytopenia. Intern Med. 2013;52(19):2193-201. doi: 10.2169/internalmedicine.52.0324. Epub 2012 Mar 1. PubMed PMID: 24088751.
Oshima Y, Yuji K, Tojo A. Eltrombopag in refractory aplastic anemia. N Engl J Med. 2012 Sep 20;367(12):1162; author reply 1163. doi: 10.1056/NEJMc1209254. PubMed PMID: 22992084.
Tanimoto T, Kusumi E, Hosoda K, Tajima F, Oshima Y. CNS prophylaxis in diffuse large B-cell lymphoma. Lancet. 2012 Apr 21;379(9825):1485-6; author reply 1486-7. doi: 10.1016/S0140-6736(12)60626-6. PubMed PMID: 22521065.
Oshima Y, Tojo A. [Why is the incidence of post-vaccination interstitial pneumonia high in Japan?]. Nihon Naika Gakkai Zasshi. 2012 Jan 10;101(1):186-7. doi: 10.2169/naika.101.186. PubMed PMID: 22482153.
Oshima Y, Tojo A. Attractive tools for systematic case accumulation. Int J Hematol. 2011 Oct;94(4):413-414. doi: 10.1007/s12185-011-0893-9. Epub 2011 Aug 30. PubMed PMID: 21877112.
Oshima Y, Tojo A. Pulmonary alveolar hemorrhage possibly associated with lenalidomide use. Int J Hematol. 2011 Sep;94(3):296-297. doi: 10.1007/s12185-011-0915-7. Epub 2011 Aug 20. PubMed PMID: 21858442.
Oshima Y. [Series: For attending physicians; professionalism; causality assessment between reported adverse events and suspected drugs]. Nihon Naika Gakkai Zasshi. 2011 Aug 10;100(8):2323-33. doi: 10.2169/naika.100.2323. PubMed PMID: 21899171.
Oshima Y. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration. Intern Med. 2011;50(8):845-53. doi: 10.2169/internalmedicine.50.4484. Epub 2011 Apr 15. PubMed PMID: 21498932.
Kumazaki M, Ando H, Sasaki A, Koshimizu TA, Ushijima K, Hosohata K, Oshima Y, Fujimura A. Protective effect of α-lipoic acid against arsenic trioxide-induced acute cardiac toxicity in rats. J Pharmacol Sci. 2011;115(2):244-8. doi: 10.1254/jphs.10280sc. Epub 2011 Jan 26. PubMed PMID: 21282932.
Murashige N, Tanimoto T, Oshima Y. Interstitial lung disease and gefitinib. N Engl J Med. 2010 Oct 14;363(16):1578-9; author reply 1579-80. doi: 10.1056/NEJMc1008506. PubMed PMID: 20942679.
Sasaki A, Oshima Y, Fujimura A. An approach to elucidate potential mechanism of renal toxicity of arsenic trioxide. Exp Hematol. 2007 Feb;35(2):252-62. doi: 10.1016/j.exphem.2006.10.004. PubMed PMID: 17258074.
Ando H, Oshima Y, Yanagihara H, Hayashi Y, Takamura T, Kaneko S, Fujimura A. Profile of rhythmic gene expression in the livers of obese diabetic KK-A(y) mice. Biochem Biophys Res Commun. 2006 Aug 11;346(4):1297-302. doi: 10.1016/j.bbrc.2006.06.044. Epub 2006 Jun 16. PubMed PMID: 16793009.
Oshima Y, Tojo A, Fujimura A, Niho Y, Asano S. Potent receptor-mediated cytotoxicity of granulocyte colony-stimulating factor-Pseudomonas exotoxin, a fusion protein against myeloid leukemia cells. Biochem Biophys Res Commun. 2004 Jun 25;319(2):582-9. doi: 10.1016/j.bbrc.2004.05.030. PubMed PMID: 15178446.
Oshima Y, Kurokawa S, Tokue A, Mano H, Saito K, Suzuki M, Imai M, Fujimura A. Primary cell preparation of human renal tubular cells for transcriptome analysis. Toxicol Mech Methods. 2004;14(5):309-16. doi: 10.1080/15376520490434647. PubMed PMID: 20021111.
Oshima Y, Ueda M, Yamashita Y, Choi YL, Ota J, Ueno S, Ohki R, Koinuma K, Wada T, Ozawa K, Fujimura A, Mano H. DNA microarray analysis of hematopoietic stem cell-like fractions from individuals with the M2 subtype of acute myeloid leukemia. Leukemia. 2003 Oct;17(10):1990-7. doi: 10.1038/sj.leu.2403098. PubMed PMID: 14513049.
Oshima Y, Fujimura A. Function of a conserved residue in the amino terminal alpha-helix of four helical bundle cytokines. Cytokine. 2003 Oct;24(1-2):36-45. doi: 10.1016/s1043-4666(03)00268-0. PubMed PMID: 14561489.
Oshima Y, Fujimura A. Implication for how the single nucleotide polymorphism (SNP) of Fc receptor, Fc gamma RIIIa alters the interaction with anti-CD20 monoclonal antibody. Blood. 2002 Jun 15;99(12):4649; author reply 4650. doi: 10.1182/blood-2002-02-0480. PubMed PMID: 12066789.
Oshima Y, Puri RK. Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist. Cell Immunol. 2001 Jul 10;211(1):37-42. doi: 10.1006/cimm.2001.1828. PubMed PMID: 11585386.
Oshima Y, Puri RK. A novel interleukin 13 (IL-13) antagonist that blocks the biological activity of human IL-13 in immune and nonimmune cells. FASEB J. 2001 Jun;15(8):1469-71. doi: 10.1096/fj.00-0711fje. PubMed PMID: 11387260.
Oshima Y, Puri RK. Characterization of a powerful high affinity antagonist that inhibits biological activities of human interleukin-13. J Biol Chem. 2001 May 4;276(18):15185-91. doi: 10.1074/jbc.M010159200. Epub 2001 Jan 26. PubMed PMID: 11278629.
Oshima Y, Joshi BH, Puri RK. Conversion of interleukin-13 into a high affinity agonist by a single amino acid substitution. J Biol Chem. 2000 May 12;275(19):14375-80. doi: 10.1074/jbc.275.19.14375. PubMed PMID: 10799519.
Oshima Y, Tojo A, Niho Y, Asano S. Biological activity of human granulocyte colony stimulating factor with a modified C-terminus. Biochem Biophys Res Commun. 2000 Jan 27;267(3):924-7. doi: 10.1006/bbrc.1999.2062. PubMed PMID: 10673392.
Oshima Y, Nishida K, Kawazoye S, Noda T, Arima F, Miyahara M, Higashijima M, Yanaga T. Successful treatment of cytomegalovirus colitis with ganciclovir in a patient with adult T cell leukemia lymphoma: case report. J Chemother. 1999 Jun;11(3):215-9. doi: 10.1179/joc.1999.11.3.215. PubMed PMID: 10435685.
Oshima Y, Ideguchi H, Takao M, Okamura T, Arima F, Miyahara M, Yanaga T, Niho Y. A patient with a hemoglobin variant (Hb JLome) unexpectedly detected by HPLC for glycated hemoglobin (Hb A1c). Int J Hematol. 1998 Oct;68(3):317-21. doi: 10.1016/s0925-5710(98)00077-2. PubMed PMID: 9846016.
Takahashi S, Oshima Y, Okamoto S, Nishiwaki K, Nagayama H, Inoue T, Tojo A, Tani K, Asano S. Recombinant human granulocyte colony-stimulating factor (G-CSF) combined conditioning regimen for allogeneic bone marrow transplantation (BMT) in standard-risk myeloid leukemia. Am J Hematol. 1998 Apr;57(4):303-8. doi: 10.1002/(sici)1096-8652(199804)57:4<303::aid-ajh6>;2-y. PubMed PMID: 9544974.
Oshima Y, Takahashi S, Nagayama H, Nishiwaki K, Kobayashi Y, Tojo A, Okamoto S, Tani K, Ozawa K, Wakabayashi T, Sato N, Kobayashi S, Nakamura K, Ohya Y, Nukina N, Kanazawa I, Asano S. Fatal GVHD demonstrating an involvement of respiratory muscle following donor leukocyte transfusion (DLT). Bone Marrow Transplant. 1997 Apr;19(7):737-40. doi: 10.1038/sj.bmt.1700731. PubMed PMID: 9156252.
Nishida K, Seto M, Takahashi T, Oshima Y, Asano S, Tojo A, Ueda R. In vitro effects of a recombinant toxin, mSCF-PE40, targeting c-kit receptors ectopically expressed in small cell lung cancers. Cancer Lett. 1997 Feb 26;113(1-2):153-8. doi: 10.1016/s0304-3835(96)04593-4. PubMed PMID: 9065815.
Nakayama M, Takahashi S, Inoue T, Nagamura F, Setoyama M, Ooi J, Takahashi T, Oshima Y, Miyamoto K, Uemura N, Shindo E, Tajika K, Yanagisawa K, Nagayama H, Okamoto S, Tojo A, Tani K, Ozawa K, Asano S, Wakabayashi T, Sato N, Ichinose Y, Toyama K, Saito H. [Bronchiolitis obliterans organizing pneumonia (BOOP) after allogeneic bone marrow transplantation]. Rinsho Ketsueki. 1996 Nov;37(11):1271-5. PubMed PMID: 8960660.
Tojo A, Oshima Y, Ozawa K, Niho Y, Asano S. In vitro model of toxin therapy targeted against murine myeloid leukemia cells. Cancer Chemother Pharmacol. 1996;38 Suppl:S37-9. doi: 10.1007/s002800051035. PubMed PMID: 8765414.
Nakayama M, Kobayashi Y, Oshima Y, Uemura N, Shindo E, Tajika K, Yanagisawa K, Takahashi S, Irie S, Tojo A. [Multiple myeloma developing myelodysplastic syndrome with thrombocytosis]. Rinsho Ketsueki. 1995 Jul;36(7):703-6. PubMed PMID: 7563601.
Tojo A, Oshima Y. [Targeted toxin therapy in the treatment of leukemia]. Rinsho Ketsueki. 1995 Jun;36(6):578-81. PubMed PMID: 7543952.
What would you like to do?
  • Page of 1